Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Oncotarget

Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G.
PMID: 29515765
Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09.

The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN...

Cite
Montalban-Bravo G, Takahashi K, Patel K, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018;9(11):9714-9727doi: 10.18632/oncotarget.23882.
Montalban-Bravo, G., Takahashi, K., Patel, K., Wang, F., Xingzhi, S., Nogueras, G. M., Huang, X., Pierola, A. A., Jabbour, E., Colla, S., Gañan-Gomez, I., Borthakur, G., Daver, N., Estrov, Z., Kadia, T., Pemmaraju, N., Ravandi, F., Bueso-Ramos, C., Chamseddine, A., Konopleva, M., Zhang, J., Kantarjian, H., Futreal, A., & Garcia-Manero, G. (2018). Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 9(11), 9714-9727. https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo, Guillermo, et al. "Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms." Oncotarget vol. 9,11 (2018): 9714-9727. doi: https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09. PMID: 29515765; PMCID: PMC5839396.
Copy Download .nbib Format: NLM
Autonomic Dysfunction after Mild Traumatic Brain Injury.

Brain sciences

Esterov D, Greenwald BD.
PMID: 28800081
Brain Sci. 2017 Aug 11;7(8). doi: 10.3390/brainsci7080100.

A mild traumatic brain injury (mTBI) is a complex pathophysiologic process that has a systemic effect on the body aside from solely an impairment in cognitive function. Dysfunction of the autonomic nervous system (ANS) has been found to induce...

Cite
Esterov D, Greenwald BD. Autonomic Dysfunction after Mild Traumatic Brain Injury. Brain Sci. 2017;7(8)doi: 10.3390/brainsci7080100.
Esterov, D., & Greenwald, B. D. (2017). Autonomic Dysfunction after Mild Traumatic Brain Injury. Brain sciences, 7(8), . https://doi.org/10.3390/brainsci7080100
Esterov, Dmitry, and Greenwald, Brian D. "Autonomic Dysfunction after Mild Traumatic Brain Injury." Brain sciences vol. 7,8 (2017). doi: https://doi.org/10.3390/brainsci7080100
Esterov D, Greenwald BD. Autonomic Dysfunction after Mild Traumatic Brain Injury. Brain Sci. 2017 Aug 11;7(8). doi: 10.3390/brainsci7080100. PMID: 28800081; PMCID: PMC5575620.
Copy Download .nbib Format: NLM
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Frontiers in oncology

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.
PMID: 30319961
Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

No abstract available.

Cite
Boddu P, Borthakur G, Koneru M, et al. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018;8:369doi: 10.3389/fonc.2018.00369.
Boddu, P., Borthakur, G., Koneru, M., Huang, X., Naqvi, K., Wierda, W., Bose, P., Jabbour, E., Estrov, Z., Burger, J., Alvarado, Y., Deshmukh, A., Patel, A., Cavazos, A., Han, L., Cortes, J. E., Kantarjian, H., Andreeff, M., & Konopleva, M. (2018). Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in oncology, 8369. https://doi.org/10.3389/fonc.2018.00369
Boddu, Prajwal, et al. "Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia." Frontiers in oncology vol. 8 (2018): 369. doi: https://doi.org/10.3389/fonc.2018.00369
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018. PMID: 30319961; PMCID: PMC6167965.
Copy Download .nbib Format: NLM
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Frontiers in immunology

Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K.
PMID: 29379494
Front Immunol. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773. eCollection 2017.

Chronic lymphocytic leukemia (CLL) cells possess regulatory functions comparable to those of normal B10 cells, a regulatory B cell subset that suppresses effector T-cell function through STAT3-mediated IL-10 production. However, the mechanisms governing IL-10 production by CLL cells are...

Cite
Shaim H, Estrov Z, Harris D, et al. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2018;8:1773doi: 10.3389/fimmu.2017.01773.
Shaim, H., Estrov, Z., Harris, D., Hernandez Sanabria, M., Liu, Z., Ruvolo, P., Thompson, P. A., Ferrajoli, A., Daher, M., Burger, J., Muftuoglu, M., Imahashi, N., Li, L., Liu, E., Alsuliman, A. S., Basar, R., Nassif Kerbauy, L., Sobieski, C., Gokdemir, E., Kondo, K., Wierda, W., Keating, M., Shpall, E. J., & Rezvani, K. (2017). The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Frontiers in immunology, 81773. https://doi.org/10.3389/fimmu.2017.01773
Shaim, Hila, et al. "The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide." Frontiers in immunology vol. 8 (2017): 1773. doi: https://doi.org/10.3389/fimmu.2017.01773
Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773. eCollection 2017. PMID: 29379494; PMCID: PMC5775272.
Copy Download .nbib Format: NLM
First report of .

New microbes and new infections

Almuzara M, Cittadini R, Estraviz ML, Ellis A, Vay C.
PMID: 29922468
New Microbes New Infect. 2018 Mar 20;24:4-7. doi: 10.1016/j.nmni.2018.03.003. eCollection 2018 Jul.

The association of

Cite
Almuzara M, Cittadini R, Estraviz ML, et al. First report of . New Microbes New Infect. 2018;24:4-7doi: 10.1016/j.nmni.2018.03.003.
Almuzara, M., Cittadini, R., Estraviz, M. L., Ellis, A., & Vay, C. (2018). First report of . New microbes and new infections, 244-7. https://doi.org/10.1016/j.nmni.2018.03.003
Almuzara, M, et al. "First report of ." New microbes and new infections vol. 24 (2018): 4-7. doi: https://doi.org/10.1016/j.nmni.2018.03.003
Almuzara M, Cittadini R, Estraviz ML, Ellis A, Vay C. First report of . New Microbes New Infect. 2018 Mar 20;24:4-7. doi: 10.1016/j.nmni.2018.03.003. eCollection 2018 Jul. PMID: 29922468; PMCID: PMC6004729.
Copy Download .nbib Format: NLM
Therapy-related myelofibrosis does not appear to exist.

Blood advances

Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S.
PMID: 29296729
Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13.

There is no evidence to support the existence of therapy-related myelofibrosis.Therapy for previous malignancy has no impact on myelofibrosis prognosis.

Cite
Masarova L, Todisco G, Manshouri T, et al. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017;1(14):863-866doi: 10.1182/bloodadvances.2017007369.
Masarova, L., Todisco, G., Manshouri, T., Newberry, K. J., Cortes, J. E., Kantarjian, H. M., Estrov, Z., & Verstovsek, S. (2017). Therapy-related myelofibrosis does not appear to exist. Blood advances, 1(14), 863-866. https://doi.org/10.1182/bloodadvances.2017007369
Masarova, Lucia, et al. "Therapy-related myelofibrosis does not appear to exist." Blood advances vol. 1,14 (2017): 863-866. doi: https://doi.org/10.1182/bloodadvances.2017007369
Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13. PMID: 29296729; PMCID: PMC5737601.
Copy Download .nbib Format: NLM
Robust Biofilm-Forming .

Foods (Basel, Switzerland)

Ostrov I, Paz T, Shemesh M.
PMID: 31010041
Foods. 2019 Apr 20;8(4). doi: 10.3390/foods8040134.

One of the main strategies for maintaining the optimal hygiene level in dairy processing facilities is regular cleaning and disinfection, which is incorporated in the cleaning-in-place (CIP) regimes. However, a frail point of the CIP procedures is their variable...

Cite
Ostrov I, Paz T, Shemesh M. Robust Biofilm-Forming . Foods. 2019;8(4)doi: 10.3390/foods8040134.
Ostrov, I., Paz, T., & Shemesh, M. (2019). Robust Biofilm-Forming . Foods (Basel, Switzerland), 8(4), . https://doi.org/10.3390/foods8040134
Ostrov, Ievgeniia, et al. "Robust Biofilm-Forming ." Foods (Basel, Switzerland) vol. 8,4 (2019). doi: https://doi.org/10.3390/foods8040134
Ostrov I, Paz T, Shemesh M. Robust Biofilm-Forming . Foods. 2019 Apr 20;8(4). doi: 10.3390/foods8040134. PMID: 31010041; PMCID: PMC6518050.
Copy Download .nbib Format: NLM
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.

Oncotarget

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z.
PMID: 33747356
Oncotarget. 2021 Mar 02;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 02.

The glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces...

Cite
Rozovski U, Harris DM, Li P, et al. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021;12(5):401-411doi: 10.18632/oncotarget.27884.
Rozovski, U., Harris, D. M., Li, P., Liu, Z., Jain, P., Manshouri, T., Veletic, I., Ferrajoli, A., Bose, P., Thompson, P., Jain, N., Verstovsek, S., Wierda, W., Keating, M. J., & Estrov, Z. (2021). STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget, 12(5), 401-411. https://doi.org/10.18632/oncotarget.27884
Rozovski, Uri, et al. "STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells." Oncotarget vol. 12,5 (2021): 401-411. doi: https://doi.org/10.18632/oncotarget.27884
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 02. PMID: 33747356; PMCID: PMC7939524.
Copy Download .nbib Format: NLM
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.

Cancer

Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM.
PMID: 33449377
Cancer. 2021 Jun 01;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15.

BACKGROUND: New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high-risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell...

Cite
Abou Dalle I, Kantarjian HM, Ravandi F, et al. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021;127(11):1894-1900doi: 10.1002/cncr.33409.
Abou Dalle, I., Kantarjian, H. M., Ravandi, F., Daver, N., Wang, X., Jabbour, E., Estrov, Z., DiNardo, C. D., Pemmaraju, N., Ferrajoli, A., Jain, N., Wang, S. A., Jammal, N., Borthakur, G., Naqvi, K., Pelletier, S., Pierce, S., Andreeff, M., Garcia-Manero, G., Cortes, J. E., & Kadia, T. M. (2021). Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer, 127(11), 1894-1900. https://doi.org/10.1002/cncr.33409
Abou Dalle, Iman, et al. "Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission." Cancer vol. 127,11 (2021): 1894-1900. doi: https://doi.org/10.1002/cncr.33409
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 Jun 01;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15. PMID: 33449377.
Copy Download .nbib Format: NLM
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Blood advances

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.
PMID: 29296774
Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1)...

Cite
Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1(17):1312-1323doi: 10.1182/bloodadvances.2017008227.
Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., DiNardo, C. D., Benton, C. B., Takahashi, K., Estrov, Z., Pierce, S. R., Andreeff, M., Cortes, J. E., & Kadia, T. M. (2017). Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood advances, 1(17), 1312-1323. https://doi.org/10.1182/bloodadvances.2017008227
Boddu, Prajwal, et al. "Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis." Blood advances vol. 1,17 (2017): 1312-1323. doi: https://doi.org/10.1182/bloodadvances.2017008227
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25. PMID: 29296774; PMCID: PMC5727976.
Copy Download .nbib Format: NLM
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.

Oncotarget

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.
PMID: 30263097
Oncotarget. 2018 Sep 14;9(72):33710-33718. doi: 10.18632/oncotarget.26110. eCollection 2018 Sep 14.

Signal transducer and activator of transcription (STAT)-3 might be phosphorylated or acetylated. Unlike the phosphorylation of STAT3, little is known about the acetylation of STAT3 in chronic lymphocytic leukemia (CLL) cells. Because acetylation activates STAT3 transcription, we sought to...

Cite
Rozovski U, Harris DM, Li P, et al. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018;9(72):33710-33718doi: 10.18632/oncotarget.26110.
Rozovski, U., Harris, D. M., Li, P., Liu, Z., Jain, P., Ferrajoli, A., Burger, J., Thompson, P., Jain, N., Wierda, W., Keating, M. J., & Estrov, Z. (2018). STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget, 9(72), 33710-33718. https://doi.org/10.18632/oncotarget.26110
Rozovski, Uri, et al. "STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells." Oncotarget vol. 9,72 (2018): 33710-33718. doi: https://doi.org/10.18632/oncotarget.26110
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14;9(72):33710-33718. doi: 10.18632/oncotarget.26110. eCollection 2018 Sep 14. PMID: 30263097; PMCID: PMC6154750.
Copy Download .nbib Format: NLM
Poster 110 Acute Rehabilitation of MI Complicated by Cardiogenic Shock Requiring ECMO, Resulting in Necrotizing Fasciitis and AKA with Subsequent LifeVest Placement: A Case Report.

PM & R : the journal of injury, function, and rehabilitation

Esterov D, Kim K, Cuccurullo SJ, Jafri IH.
PMID: 27672878
PM R. 2016 Sep;8(9):S197. doi: 10.1016/j.pmrj.2016.07.153. Epub 2016 Sep 24.

No abstract available.

Cite
Esterov D, Kim K, Cuccurullo SJ, et al. Poster 110 Acute Rehabilitation of MI Complicated by Cardiogenic Shock Requiring ECMO, Resulting in Necrotizing Fasciitis and AKA with Subsequent LifeVest Placement: A Case Report. PM R. 2016;8(9):S197doi: 10.1016/j.pmrj.2016.07.153.
Esterov, D., Kim, K., Cuccurullo, S. J., & Jafri, I. H. (2016). Poster 110 Acute Rehabilitation of MI Complicated by Cardiogenic Shock Requiring ECMO, Resulting in Necrotizing Fasciitis and AKA with Subsequent LifeVest Placement: A Case Report. PM & R : the journal of injury, function, and rehabilitation, 8(9), S197. https://doi.org/10.1016/j.pmrj.2016.07.153
Esterov, Dmitry, et al. "Poster 110 Acute Rehabilitation of MI Complicated by Cardiogenic Shock Requiring ECMO, Resulting in Necrotizing Fasciitis and AKA with Subsequent LifeVest Placement: A Case Report." PM & R : the journal of injury, function, and rehabilitation vol. 8,9 (2016): S197. doi: https://doi.org/10.1016/j.pmrj.2016.07.153
Esterov D, Kim K, Cuccurullo SJ, Jafri IH. Poster 110 Acute Rehabilitation of MI Complicated by Cardiogenic Shock Requiring ECMO, Resulting in Necrotizing Fasciitis and AKA with Subsequent LifeVest Placement: A Case Report. PM R. 2016 Sep;8(9):S197. doi: 10.1016/j.pmrj.2016.07.153. Epub 2016 Sep 24. PMID: 27672878.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries